Cancer | Product Monograph | SciClone Pharmaceuticals International

Home

Contact

Site Map

Cancer

Key Takeaways

•	In HCC, Zadaxin in combination with TACE doubles survival rate at 7 months.
•	Zadaxin plus TACE significantly increases survival post treatment compared with TACE alone.
•	In NSCLC, Zadaxin treatment following radiation therapy increases T-cell levels and significantly improves overall survival.
•	Zadaxin helps to maintain CD4 and CD8 cell counts during and after chemotherapy.
•	In malignant melanoma, Zadaxin plus IFN more than doubles the response rate to DTIC alone.
•	Zadaxin has not been shown to add to side effects from front-line cancer treatments.